A detailed history of Evergreen Capital Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Evergreen Capital Management LLC holds 2,636 shares of VRTX stock, worth $1.24 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
2,636
Previous 2,416 9.11%
Holding current value
$1.24 Million
Previous $1.01 Million 22.4%
% of portfolio
0.05%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $86,418 - $106,816
220 Added 9.11%
2,636 $1.24 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $4,892 - $5,352
12 Added 0.5%
2,416 $1.01 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $17,836 - $21,355
-52 Reduced 2.12%
2,404 $978,000
Q3 2023

Nov 14, 2023

SELL
$338.18 - $362.46 $3,719 - $3,987
-11 Reduced 0.45%
2,456 $854,000
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $295,240 - $330,443
939 Added 61.45%
2,467 $868,000
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $16,993 - $19,386
60 Added 4.09%
1,528 $481,000
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $5,143 - $5,786
18 Added 1.24%
1,468 $423,000
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $122,675 - $136,877
448 Added 44.71%
1,450 $420,000
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $39,238 - $48,855
-167 Reduced 14.29%
1,002 $283,000
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $51,148 - $60,284
231 Added 24.63%
1,169 $305,000
Q4 2021

Mar 11, 2022

BUY
$177.01 - $223.45 $166,035 - $209,596
938 New
938 $206,000
Q3 2020

Nov 16, 2020

SELL
$255.65 - $303.1 $189,436 - $224,597
-741 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $167,080 - $219,187
741 New
741 $215,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Evergreen Capital Management LLC Portfolio

Follow Evergreen Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Evergreen Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Evergreen Capital Management LLC with notifications on news.